Source:  Cannabis Science, Inc. Press Release / May 22 2014

COLORADO SPRINGS, Colo., May 22, 2014 /PRNewswire/ — Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders.

To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer’s disease.

Earlier this year the company has raised funds to facilitate Cannabis Science’s R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the Company’s new product to address neurobehavioral disorders.

“Cannabis Science has made solid progress so far this year. I am proud to be a part of this team and I am very positive about our future,” stated Robert Kane, CFO of Cannabis Science.

In conjunction the Company is discussing the initiation of additional clinical studies using pharmaceutical grade cannabis in proprietary, topical and orally administered applications to various skin conditions including skin cancer work to be conducted in several geographic areas in collaboration with multiple potential partners.

The company is finalizing discussions with further research groups to ensure timely completion of the planned development. Following the completion of the toxicity and the pre-clinical efficacy studies the company plans to proceed into clinical studies during the next year.  Work has also been initiated on the formulations and negotiations are underway to establish several commercial partnerships in this area.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
[email protected]
[email protected]
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
[email protected]
Tel: 1. 561.420.4824

SOURCE Cannabis Science, Inc.


Source: PR Newswire (May 22, 2014 – 7:00 AM EDT)News by QuoteMedia